【特约大V】邓声兴:美通胀降温缓加息忧虑,恒指有望随科网股反弹

金吾财讯
Jul 16

金吾财讯 | 恒指周三(15日)收市报24681点,升340点或1.4%。大市全日成交3042亿元。国指升81点或1%,报8184点;科指升61点或1.3%,报4740点。中国人寿(02628)料上半年多赚逾2.1倍,股价先升后跌2.2%,报28元。人工智能(AI)股智谱(02513)升6.7%,报1707元;稀宇科技(MiniMax)(00100)升13.3%,报260.6元。长飞光纤光缆(06869)料上半年盈利增长逾7.1倍,并获大摩上调长公司H股评级至“增持”,股价收升1.6%,报156.4元。道指周三(15日)收市报52658点,升150点或0.29%;标指涨0.38%,报7572点;纳指上扬0.62%,报26269点;芯片巨头辉达(Nvidia)股价一度下挫2.7%,收市转升0.3%,英特尔(Intel)跌4.4%,美光滑落8%。其他科技股中,苹果公司和微软分别涨4%和2.8%,苹果是升幅最大道指成份股,并创即市和收市历史新高,市值达到4.81万亿美元,阿里巴巴(09988)称旗下千问AI将整合至苹果智能系统中,供中国用户使用;Alphabet扬3.2%,亚马逊抽高3%;电脑生产商戴尔(Dell)挫9.9%,思科下挫4.5%,为表现最差道指成份股。亚太股市今早(16日)个别走,日经225指数现时报66825点,跌1926点或2.8%。台湾加权指数指数现时报45114点,跌517点或1.13%。美通胀降温缓加息忧虑,恒指有望随科网股反弹。信达生物(01801)信达生物近期正从“PD-1单一引擎”迈向“肿瘤+自免+眼科”多维成长曲线,最瞩目者莫过于与Spero Therapeutics就IBI355(第三代Fc沉默型抗CD40L单抗)达成独家许可协议,信达授予Spero大中华区以外全球权益,交易总额高达约11亿美元,涵盖首付款、里程碑付款及销售分成;Spero计划2027年第二季启动IgG4-RD的II期研究,信达则于2027年初在中国启动干燥综合症的II期研究。与此同时,集团与礼来就CDK4/6抑制剂唯择(阿贝西利片)在中国大陆达成商业化合作,信达负责进口、销售、推广及分销,礼来负责生产供应,此举有助强化肿瘤产品组合协同效应及渠道覆盖效率。此外,合作伙伴Ollin Biosciences完成3.3亿美元B轮融资,将用于推进IBI324(VEGF/Ang2双抗)全球III期临床开发,眼科大适应症(DME/wAMD)市场空间广阔,融资到位亦侧面印证外部资本对信达管线价值的认可。信达生物正处于海外BD持续兑现、肿瘤基本盘稳健增长及自免眼科管线价值重估的三重交汇点,中线估值修复空间值得关注。目标价120,止蚀价$87(笔者为证监会持牌人士及笔者未持有上述股份)

作者:香港股票分析师协会主席邓声兴博士

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10